Theriva Biologics Reports Q3 2026 Net Loss of $1.5 Million, Advances VCN-01 Trial

Theriva Biologics reported a third-quarter 2026 net loss of $1.5 million, compared with a $4.4 million loss in the same quarter a year earlier. Cash and cash equivalents were $8.5 million at September 30, 2026, and the company said its cash runway extended into the first quarter of 2027. The compan…